Regeneron Pharmaceuticals (REGN) EBT Margin (2009 - 2026)

Regeneron Pharmaceuticals' EBT Margin history runs 18 years deep, the most recent figure standing at 23.05% for Q1 2026.

• In Q1 2026, EBT Margin fell 683.0% year-over-year to 23.05%; the TTM figure through Mar 2026 stood at 34.56% (down 82.0% YoY), while the FY2025 annual figure was 36.47%, up 281.0% from the prior year.
• EBT Margin was 23.05% for Q1 2026 at Regeneron Pharmaceuticals, down from 26.87% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 2122.2% in Q1 2022 to a low of 22.28% in Q1 2024.
• Historically, EBT Margin has averaged 233.03% across 5 years, with a median of 33.71% in 2022.
• The sharpest annual moves came in 2022 and 2023: EBT Margin soared 207265 bps in 2022, then slumped 209507 bps in 2023.
• A 5-year view of EBT Margin shows it stood at 1324.7% in 2022, then slumped by 97 bps to 33.42% in 2023, then dropped by 24 bps to 25.29% in 2024, then rose by 6 bps to 26.87% in 2025, then dropped by 14 bps to 23.05% in 2026.
• The last three EBT Margin figures came in at 23.05% (Q1 2026), 26.87% (Q4 2025), and 46.97% (Q3 2025), per Business Quant data.